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Oral loading of propafenone:
restoring its role before
restoring rhythm
The optimal way to convert recent onset atrial
fibrillation (AF) to sinus rhythm is still a matter of
interest for physicians. According to guidelines,
usually the clinical strategy depends on patient’s
characteristics. Pharmacological cardioversion
with Class I antiarrhythmic drugs is one of the
main therapeutic options for restoring sinus
rhythm in patients with recent onset and haemo-
dynamically well-tolerated AF, in the absence of
structural heart disease.
Stoschitzky et al.1 investigated the effects of a
single oral dose of 600 mg propafenone in 12
healthy males: they found that a single oral loading
dose decreases heart rate, systolic blood pres-
sure, and rate pressure product. They also
observed an increased plasma concentration of
propafenone during exercise and its reduction
during recovery. On the basis of their observa-
tions, the Authors concluded that propafenone
also exerts a b-blocking activity, and in their view,
this might allow the use of oral propafenone load-
ing also in patients with structural heart disease.
The b-blocking effect of propafenone had
already been observed in previous studies, along
with mild calcium channel-blocking effect, and an
inhibition of potassium currents, particularly Ik.
2
The pharmacokinetics of propafenone are also
complex: it undergoes extensive first-pass hepatic
metabolism to 5-hydroxy-propafenone, which
has a similar pharmacodynamic profile to the
parent drug and contributes significantly to the
therapeutic effects. Another complicating factor is
that 5–10% of Caucasians (so-called ‘poor oxidiz-
ers’) have a reduced oxidative metabolic capacity
that leads to low or even undetectable concentra-
tions of 5-hydroxy-propafenone and high plasma
concentrations of the parent drug.3
Even though the safety profile of a single oral
loading dose of propafenone is high, there is a
potential pro-arrhythmic risk: conversion of AF in
atrial flutter with 1:1 atrioventricular conduction
(and wide QRS) occurs in 3.5–5% of patients
treated with Class 1C antiarrhythmic drugs. To
prevent this undesired side effect, Marcus et al.4
suggested to administer b-blockers with Class 1C
antiarrhythmic drugs, since the early 90s.
Moreover, the negative inotropic effect of oral
propafenone may lead to transient hypotension
(2.5%) and rarely pulmonary oedema (0.1%).2,5
These complications may be even more
dangerous in patients with structural heart dis-
ease, coronary artery disease, or heart failure.
Furthermore, such patients are usually treated
with complex drug regimens, increasing the risk of
pharmacological interference and relevant clinical
side effects.
Consistently with previous observations, prop-
afenone should be avoided (even in a single oral
loading dose) in elderly patients (aged >80), those
with heart failure (New York Heart Association
functional class >II), left ventricular dysfunction
(ejection fraction <40–45%), ischaemic heart dis-
ease, systolic arterial pressure <95–100 mmHg,
baseline QRS interval duration >_0.11 s, previous
evidence of second- or third-degree atrioventric-
ular block, sick sinus syndrome, renal or liver fail-
ure, hypokalaemia, or concurrent treatment with
other antiarrhythmic agents.2,5
In conclusion, despite the interesting findings of
Stoschitzky et al.1 in healthy young volunteers, we
discourage the use of propafenone in patients
with structural heart disease, (considering its well-
documented potential negative inotropic and
pro-arrhythmic effect) until larger trials are per-
formed in such patients.
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We wish to thank Martignani et al.1 for their crit-
ical Letter to the Editor according to our article
recently published in Europace2 where they ques-
tion our proposal that propafenone should not be
generally excluded from cardioversion of parox-
ysmal atrial fibrillation in patients with structural
heart disease. Recent 2016 European Society of
Cardiology Guidelines for the Management of Atrial
Fibrillation3 support the use of propafenone for
acute pharmacological cardioversion in patients
with new onset of atrial fibrillation. However,
their restriction that propafenone should only be
given to patients without structural heart disease3
particularly bases on CAST (the Cardiac
Arrhythmias Suppression Trial),4 where long-term
administration of flecainide and encainide, two
other Class Ic antiarrhythmic agents without b-
blocking effects, increased mortality when given
to patients with ventricular arrhythmias and cor-
onary artery disease.
Our data and conclusions2 only refer to the ad-
ministration of single oral doses of propafenone
for cardioversion of paroxysmal atrial fibrillation.
Therefore, the fact that the pharmacokinetics of
propafenone may be different in different oxi-
disers5 only plays a minor role since we do not
recommend long-term treatment.
There is no doubt that administration of Class
Ic antiarrhythmic drugs in patients with atrial fibril-
lation may switch to atrial flutter and that, there-
fore, concomitant treatment with a b-blocker or
a non-dihydropyridine calcium channel blocker is
recommended.3 Therefore, it might be essential
that single oral doses of 600 mg propafenone pos-
sess b-blocking effects by themselves.2
We fully agree that b-blockers show several
side effects and contraindications such as asthma
bronchiale, severe obstructive lung disease, sys-
tolic heart failure, hypotension, atrio-ventricular-
blocks, and sick sinus syndrome.1 Therefore,
even single oral doses of propafenone should
be given carefully to patients with these
diseases.
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